33 results
Thumbnail

D1.327 - Genetic Analysis of Children with Suspected Immunodeficiency: Mimickers of Inborn Errors of Immunity

Thumbnail

D1.329 - Late-Childhood Diagnosis of DNA Methyltransferase 3B Deficiency-ICF1 Syndrome

Thumbnail

D1.322 - Clinical Cardiovascular Safety Assessment of Oral Deucrictibant

Thumbnail

D1.323 - Assessing Immune Responses to Conjugate Pneumococcal Vaccination in Infants with Transient and Unclassified Hypogammaglobulinemia:Insights from a Tertiary Pediatric Center

Thumbnail

D1.324 - JAK Inhibitors in the Treatment of Chronic Mucocutaneous Candidiasis in a Patient with STAT1 Gain-of-Function Mutation

Thumbnail

D1.326 - Behind The Scenes: Primary Immunodeficiencies in Pediatric Eosinophilic Gastrointestinal Diseases

Thumbnail

D1.328 - CARD11 Dominant-Negative Mutation Presenting with Early Severe Bacterial Sepsis, Viral Susceptibility, and Alopecia Totalis in a Child

Thumbnail

D1.330 - Two different clinical presentations, two same immunological features in Purin nucleoside phosporilase deficiency

Thumbnail

D1.331 - Analysis of early complement parameters and C1INH values in newborns with a positive family history of HAE-C1INH

Thumbnail

D1.333 - Digital clinical registry pilot for hereditary angioedema: standardized monthly real-world monitoring of C1 inhibitor deficiency in Serbia

Thumbnail

D1.334 - Association of Multiple Endocrinopaties with Immune Dysregulation, Allergies and Primary Immunodeficiency

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)